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Abstract
Background: The development of an immunocompetent, genetically modified mouse model to
study HIV-1 pathogenesis and to test antiviral strategies has been hampered by the fact that cells
from native mice do not or only inefficiently support several steps of the HIV-1 replication cycle.
Upon HIV-1 infection, mouse T-cell lines fail to express viral proteins, but the underlying replication
barrier has thus far not been unambiguously identified. Here, we performed a kinetic and
quantitative assessment of consecutive steps in the early phase of the HIV-1 replication cycle in T-
cells from mice and humans.
Results: Both T-cell lines and primary T-cells from mice harbor a severe post-entry defect that is
independent of potential species-specTR transactivation. Reverse transcription occurred efficiently
following VSV-G-mediated entry of virions into mouse T-cells, and abundant levels of 2-LTR circles
indicated successful nuclear import of the pre-integration complex. To probe the next step in the
retroviral replication cycle, i.e. the integration of HIV-1 into the host cell genome, we established
and validated a nested real-time PCR to specifically quantify HIV-1 integrants exploiting highly
repetitive mouse B1  elements. Importantly, we demonstrate that the frequency of integrant
formation is diminished 18- to > 305-fold in mouse T-cell lines compared to a human counterpart,
resulting in a largely abortive infection. Moreover, differences in transgene expression from residual
vector integrants, the transcription off which is cyclin T1-independent, provided evidence for an
additional, peri-integrational deficit in certain mouse T-cell lines.
Conclusion: In contrast to earlier reports, we find that mouse T-cells efficiently support early
replication steps up to and including nuclear import, but restrict HIV-1 at the level of chromosomal
integration.
Background
Human immunodeficiency virus type 1 (HIV-1) displays
a highly restricted host and cell tropism and is only capa-
ble of efficient replication in primary and immortalized T-
cells and macrophages of human origin. Cells from native
mice do not or only inefficiently support various steps of
the HIV-1 replication cycle [1-7]. The precise mapping of
some of these species-specific barriers has, on one hand,
facilitated the identification and molecular characteriza-
tion of critical host factors, and, on the other hand, high-
lighted the complexity of the task to develop genetically
altered mice that are fully permissive for HIV-1 infection.
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The by far most prominent category of barriers thus far
identified in mouse cell lines appears to be recessive in
nature. Blocks in this category are characterized by an ina-
bility of mouse orthologues of cellular proteins that are
essential cofactors for HIV-1 replication in human cells to
support distinct replication steps of the virus. HIV-1 entry
provides a compelling example since CD4 and the chem-
okine co-receptor CCR5 from mice bind the HIV-1 enve-
lope glycoprotein with presumably only low affinity and
this interaction is insufficient to support virion fusion
[4,5,8]. Moreover, the discovery that expression of the
human HIV-1 receptor complex largely overcomes the
entry restriction has provided the rationale for the devel-
opment of permissive multi-transgenic mouse and rat
models through a block-by-block humanization [9].
Along these lines, expression of the human version of the
Tat-interacting protein cyclin T1 was shown to boost HIV-
1 transcription in mouse cells in vitro and in vivo [3,7,10-
14]. Additional, less-defined blocks in the late phase of
the HIV-1 replication cycle in NIH3T3 cells add up to a
profound drop in the yield of viral progeny (up to 104-
fold) from a single round of replication [4,5,15]. Also
these late-stage barriers in mouse fibroblasts display a
recessive phenotype and likely result from non-functional
mouse cofactors since they can be surmounted in mouse-
human heterokaryons [4,5,15-17].
Cellular restriction factors, defining a different class of
barrier characterized by dominant inhibitory activities,
can interfere with lentiviral replication in a species-spe-
cific manner. Of potential relevance in the rodent context,
the incorporation of the cytidine deaminase APOBEC3G
of mouse origin into particles cannot, in contrast to its
human orthologue, be counteracted by the HIV-1 Vif pro-
tein, resulting in a pronounced reduction in particle infec-
tivity [18]. Providing another example, an early post-entry
barrier has been reported for a SIVmac reporter virus in
NIH3T3 cells, which displayed typical characteristics of a
restriction factor [19].
However, most of these replication barriers in mice have
been described in fibroblast cell lines and the efficiency of
different steps of the HIV-1 replication cycle in more rele-
vant target cells has remained elusive. More recently, a
severe post-entry defect has been reported in infected
mouse T-cells [19-21]. One study mapped this defect to a
reduced efficiency of reverse transcription and nuclear
import of the HIV-1 pre-integration complex [20]. A sec-
ond study, in contrast, suggested nuclear import to be the
sole cause of the early-phase restriction [21].
Here, we performed a kinetic and quantitative assessment
of consecutive steps in the early phase of the HIV-1 repli-
cation cycle in T-cells from mice and humans. Starting
from a single viral challenge, the efficiency of virus entry,
reverse transcription, nuclear import, the frequency of
integration, as well as transgene expression off a cytomeg-
alovirus (CMV) immediate early promoter or off the HIV-
1NL4-3  LTR were carefully monitored to pinpoint the
restriction.
Results
HIV-1-infected mouse T-cell lines do not express a CMV-
driven GFP reporter despite efficient virion entry
We first sought to establish a quantitative relationship
between the ability of HIV-1 virions to enter T-cells of
mouse and human origin and, subsequently, to express a
reporter gene in these target cells. To ensure comparable
conditions in the cross-species comparisons, we
employed an HIV-1 based lentiviral vector encoding for
GFP driven by a cytomegalovirus immediate early pro-
moter (HIV-CMV-GFP), which was pseudotyped with the
vesicular stomatitis virus glyco-protein (VSV-G). Notably,
the expression of GFP from this vector is not influenced by
HIV-1 Tat/cyclin T1-dependent, potentially species-spe-
cific differences in LTR transactivation [3]. Through incor-
poration of enzymatically active β-lactamase-Vpr fusion
proteins (BlaM-Vpr) during virus production the effi-
ciency of HIV-1 entry into target cells was specifically
measured by CCF2 substrate cleavage in a flow cytometry-
based virion-fusion assay [22,23].
Following a single challenge with this dual HIV-1 reporter
virus, T-cell lines of human and mouse origin were ana-
lyzed for virion fusion and early gene expression, 6 h p.i.
and on day 3 p.i., respectively. Fig. 1 depicts representative
flow cytometric data of both of these analyses for MT-4
(human) and S1A.TB (mouse) T-cells, in which gate R2
defines the cleaved CCF2 (blue fluorescence emission)-
positive subpopulation (Fig. 1A, B; upper panels) or the
GFP-positive subpopulation (Fig. 1A, B; lower panels) of
all viable cells (gate R1), respectively. The specificity of vir-
ion entry and viral gene expression was confirmed by neu-
tralization with an anti-VSV-G monoclonal antibody [24]
or by pretreatment with the reverse transcriptase inhibitor
efavirenz, respectively (Fig. 1; right panels).
T-cell lines from both species allowed quite similar levels
of entry of the BlaM-Vpr-loaded HIV-CMV-GFP virus
(Figs. 1A, B; upper panels), ranging on average from 10 to
31% (Fig. 2A). In stark contrast, analysis of GFP reporter
expression showed a 67- to 290-fold reduction in the per-
centage of infected mouse T-cell lines (TIMI.4; R1.1,
S1A.TB) expressing the reporter transgene compared to
human MT-4 T-cells (Figs. 1A, B; lower panels; Fig. 2B).
This degree of impairment in gene expression was also
seen when equal titres of VSV-G HIV-CMV-GFP, that did
not carry BlaM-Vpr, were used, or when gene expression
was assessed on day 7 p.i. (data not shown). In a more
refined analysis, the ratio of the percentages of cells thatRetrovirology 2008, 5:58 http://www.retrovirology.com/content/5/1/58
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Mouse T-cells do not support CMV-driven reporter gene expression following VSV-G-mediated virion entry Figure 1
Mouse T-cells do not support CMV-driven reporter gene expression following VSV-G-mediated virion entry. 
Fusion of the VSV-G pseudotyped lentiviral vector carrying BlaM-Vpr (VSV-G HIV-CMV-GFP BlaM-Vpr) and subsequent GFP 
reporter gene expression was analyzed in (A) human MT-4 and (B) mouse S1A.TB T-cell lines by flow cytometry 6 h and 3 d 
p.i., respectively. Cells were challenged with the VSV-G pseudotyped vector either in the presence of the neutralizing anti-VSV-
G monoclonal antibody I1, the NNRTI efavirenz, or left untreated. Shown are representative FACS dot plots of viable T-cells 
(gate R1; left panels) for the detection of the cleaved CCF2 substrate (gate R2; blue color; upper panels in A and B), reflecting 
HIV-1 entry, or early CMV-driven GFP expression (gate R2, lower panels in A and B). The relative percentage of cells in R2 is 
given.
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Mouse T-cell lines of different genetic background allow VSV-G-mediated HIV-1 entry, but restrict CMV-driven gene expres- sion Figure 2
Mouse T-cell lines of different genetic background allow VSV-G-mediated HIV-1 entry, but restrict CMV-
driven gene expression. Results for (A) virion fusion and (B) CMV-driven GFP gene expression for MT-4 (human), TIMI.4, 
R1.1 and S1A.TB (mouse) T-cell lines from the experiment shown in Fig. 1. Values are the arithmetic mean ± S.D. of triplicates. 
Panel C depicts the Relative-Post-Entry-Efficiency calculated as the ratio of the percentage of GFP-expressing cells (panel B) 
divided by the percentage of cleaved-CCF2-positive cells (virion fusion; panel A) × 1000 in arbitrary units. Data are represent-
ative for 3–4 independent experiments.
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scored positive for gene expression (Fig. 2B) relative to vir-
ion entry (Fig. 2A) was defined for each T-cell line as a
cumulative Relative Post-Entry Efficiency revealing a
mouse-human species differerence of 55- to 235-fold (Fig.
2C). In summary, these consecutive analysis of virion
entry and CMV-driven reporter gene expression from a
single infection corroborate the observation of a severe
post-entry block for HIV-1 in mouse T-cell lines [20,21].
HIV-1 reverse transcription and nuclear import occur 
efficiently in mouse T-cells
To characterize at which step of the replication cycle fol-
lowing entry HIV-1 encounters a block in murine T-cells,
levels of late HIV-1 cDNAs and episomal 2-LTR circles
were analyzed as markers for reverse transcription and
nuclear import of the pre-integration complex, respec-
tively. DNA was extracted from infected mouse and
human T-cell lines (from the experiment shown in Figs. 1,
2), aliquots of which were harvested 24 h p.i. and ana-
lyzed by real-time PCR. The HIV-1 cDNA species were
quantified using established protocols, specificity con-
trols, and quantitative standards for either HIV-1 cDNA
species and normalized to cellular DNA levels, which
were determined in a parallel reaction by amplification of
a cellular gene [6,25].
Following comparable levels of virion entry (Fig. 2A), lev-
els of total HIV-1 cDNA were found to be quite similar in
the cross-species comparison (Fig. 3A), suggesting an effi-
cient reverse transcription process in these rodent cells.
Similarly, levels of episomal 2-LTR circles were in the
same range or slightly elevated in mouse T-cell lines rela-
tive to the human counterpart (Fig. 3B). Following nor-
malization with levels of de novo synthesized HIV-1 cDNA
(Fig. 3A), 2-LTR circle levels (Fig. 3B) turned out to be sta-
tistically indistinguishable (data not shown). Impor-
tantly, 2-LTR circles were also detected in HIV-1-infected
primary mouse T-cells derived from splenocyte pools of 3
BALB/c mice. Levels of 2-LTR circles were comparable
(Fig. 3D; mouse donor pool #1) or ~16-fold higher (Fig.
3D; mouse donor pool #2) than in primary human T-cell
cultures, indicating that following virion entry (Fig. 3C)
the processes of reverse transcription and nuclear import
are intact in these primary mouse targets. As a specificity
control, no 2-LTR circles could be detected in efavirenz-
treated cultures, demonstrating that the amplified episo-
mal HIV-1 cDNAs had been generated from de novo syn-
thesized viral DNA and were not present in the inoculum
(data not shown). Due to the generally low infection level
and residual DNase-resistant, production-related plasmid
contaminations in virus stocks, levels of de novo synthe-
sized viral DNA could not be quantified separately in pri-
mary T-cells (data not shown). In summary, these results
suggest that following entry of virions, reverse transcrip-
tion occurs efficiently in mouse T-cells. Furthermore,
abundant levels of 2-LTR circles suggest robust import of
the pre-integration complex into the nucleus. This tenta-
tively maps the replication barrier in mouse T-cells to a
step after nuclear entry.
Establishment and validation of a quantitative nested PCR 
to detect integrated HIV-1 DNA in the mouse genome
Next, we quantified provirus formation in infected mouse
and human T-cells. In principle, a defect at the level of
integration can drastically diminish or completely abro-
gate viral gene expression [26,27]. Similar to reported
nested PCR strategies to amplify HIV-1 integrated in prox-
imity to highly abundant genomic repeat elements in
human cells (Alu elements) [28], or in rat cells (BC ele-
ments) [6], we designed a nested real-time PCR to specif-
ically quantify integrated HIV-1 provirus in mouse cells
using the most abundant consensus sequence B1 within
mouse SINE elements [29], as the repeat target for the cel-
lular anchor primer pair in the genome of this species (Fig.
4A).
To establish a standard for quantitative analyses of inte-
gration into the mouse genome, a stable polyclonal pop-
ulation of NIH3T3 fibroblasts containing integrated HIV-
1 provirus was generated by infection with VSV-G HIV-
1NL4-3 GFP at a low MOI, cell passage for 7 weeks to allow
complete loss of all unintegrated HIV-1 cDNA species,
and subsequent enrichment of GFP-positive cells by flow
cytometric sorting (thereafter referred to as NIH3T3Pint
cells), in principle as reported previously for the rat spe-
cies [6]. Since these NIH3T3Pint cells no longer contain
unintegrated HIV-1 cDNA species, the absolute number of
HIV-1 integrants was accurately quantified by the number
of total HIV-1 cDNA copies (54 HIV-1 cDNA copies per ng
DNA), thus providing a faithful reference for the integra-
tion PCR standard in the mouse genome. Fig. 4B depicts a
typical mouse HIV-1 integration standard plotted as a
function of the natural logarithm of the concentration of
HIV-1 versus the PCR cycle threshold. This standard has a
dynamic range of over 3 logs with a highest copy number
of 36.741, and both the slope and R2 value were consid-
ered as quality controls in individual experiments.
The nested PCR strategy for quantification of HIV-1 inte-
grants in mouse cells is depicted in Fig. 4A, and described
in the figure legend and under Methods. This mouse inte-
gration PCR and a human integration PCR, the latter
essentially following a published protocol [28], were val-
idated side-by-side using genomic DNA from NIH3T3int
or HeLaint  cells [6], respectively (Fig. 5A). Here, the
number of HIV-1 integrants per ng DNA for the complete
PCR reaction was set to 100% for each species. First, omis-
sion of LTR primer #1521 from the first-round PCR reac-
tion resulted in a loss of the amplification signal in both
species. Second, a reaction mix without the cellularRetrovirology 2008, 5:58 http://www.retrovirology.com/content/5/1/58
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anchor primer pair (Fig. 5A; #2194 and #2231 (mouse);
or #1519 and #1520 (human), [6]) yielded low residual
signals, most likely due to the partial formation of single-
stranded DNA from LTR-containing HIV-1 cDNA by the
first-round LTR primer, as reported [6,28]. Finally, omis-
sion of the first-round PCR reaction did not give a signal
above background (Fig. 5A), indicating that second-round
amplification of non-preamplified DNA is not of signifi-
cant concern.
Next, the mouse integration PCR was further validated in
a dynamic infection context. Levels of total HIV-1 cDNA
and integrants were quantified in parental NIH3T3
fibroblasts infected with either the integration-competent
(IN wt) HIV-CMV-GFP or an integration-defective iso-
genic HIV-1 vector (IN(D64V)), the latter carrying a cata-
lytic core mutation in integrase [30]. One day after
infection, high levels of total HIV-1 cDNA were found in
NIH3T3 cells challenged with either lentiviral vector,
while only background levels could be amplified from
efavirenz-treated controls (Fig. 5B). In DNA extracted on
day 7 p.i., integrants were readily amplified by the newly
developed real-time PCR protocol in NIH3T3 cells
infected with the IN wt vector, while the level of provirus
formation was severely reduced with the IN(D64V)
mutant (Fig. 5C). Collectively, a real-time PCR for the spe-
HIV-1 reverse transcription and nuclear import of the pre-integration complex are well supported in T-cell lines and primary  T-cells from mice following infection with VSV-G HIV-CMV-GFP Figure 3
HIV-1 reverse transcription and nuclear import of the pre-integration complex are well supported in T-cell 
lines and primary T-cells from mice following infection with VSV-G HIV-CMV-GFP. (A, B) The levels of total HIV-
1 cDNA and 2-LTR circles were quantified in infected human and mouse T-cell lines, samples being derived from the experi-
ment shown in Figs. 1, 2. One day p.i. cell aliquots were taken and the extracted DNA analyzed for HIV-1 cDNA species and a 
species-specific gene by real-time PCR as described under Methods. Triplicate samples were analyzed and data are representa-
tive for three independent experiments. (C, D) Mitogen/IL-2-activated primary T-cells from two human donors or two pools 
of splenocytes from 3 BALB/c mice were infected with VSV-G HIV-CMV-GFP BlaM-Vpr and analyzed for (C) virion fusion or 
(D) 2-LTR circles 6 h and 1d p.i., respectively. Duplicate samples were analyzed.
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cific detection and absolute quantification of HIV-1 inte-
grants in the genome of infected mouse cells was
established and validated.
Levels of HIV-1 integrants are severely reduced in infected 
mouse T-cell lines
Next, we applied the mouse integration PCR to a dynamic
VSV-G HIV-CMV-GFP infection in mouse T-cell lines.
While virion entry (Fig. 2A), reverse transcription (Fig.
3A), and nuclear import (Fig. 3B) appeared to be intact in
infected mouse T-cells, HIV-1 integrants from the identi-
cal experiment were undetectable in the genome of TIMI.4
cells and reduced 17- to > 29-fold in R1.1 and S1A.TB cells
relative to human MT-4 T-cells (Fig. 6A). To establish a
signature characteristic for individual T-cell lines in
respect to their ability to allow HIV-1 integration, we cal-
culated the Relative-Integration-Frequency defined as the
number of integrants on day 7 p.i. (Fig. 6A) relative to the
total amount of HIV-1 cDNA quantified on day 1 p.i. (Fig.
3A). Based on results from 2–5 independent experiments,
infected TIMI.4 cells were grossly impaired in their Rela-
tive-Integration-Frequency value, > 305-fold compared to
infected MT-4 cells (Fig. 6B). The two other mouse T-cell
lines, R1.1 and S1A.TB, displayed an intermediate pheno-
type with Relative-Integration-Frequency values 18- to 54-
fold lower compared to the human reference. Thus, inte-
gration into the host cell genome appears to be the para-
mount barrier imposed by mouse T-cells in the early
phase of HIV-1 replication.
Evidence for cyclin T1-independent transcriptional deficit 
in certain T-cell lines
To gain insight into the quantitative relationship between
vector integrants and transgene expression, the ratio of the
percentage of T-cells expressing GFP from the CMV IE pro-
moter and levels of integrants per cell was calculated, for
convenience termed Transgene-Expression-per-Integrant.
For the residual integrants in mouse R1.1 T-cells (Fig. 6A,
B), reporter gene expression was efficient, resulting in a
Transgene-Expression-per-Integrant value in a range simi-
lar to human MT-4 cells (Fig. 6C). In contrast, the Trans-
gene-Expression-per-Integrant value in infected S1A.TB
cells was 34-fold lower than R1.1 (Fig. 6C), indicating that
integrants in this mouse T-cell line frequently do not
result in a detectable gene expression. This suggests that at
least in some T-cell lines a defect in transgene expression
from residual integrants may impose an additional peri-
integrational limitation in the mouse species.
Establishment of a quantitative PCR for the detection of HIV-1 integrants in the mouse genome Figure 4
Establishment of a quantitative PCR for the detection of HIV-1 integrants in the mouse genome. (A) Schematic 
representation of the strategy and primers for the nested mouse integration PCR using anchor primers specific for highly 
repetitive mouse B1 elements. A mouse integration standard was generated by infection of mouse NIH3T3 fibroblasts with a 
low MOI of VSV-G HIV-1NL4-3 GFP, passaging of cells and sorting for GFP-expressing cells 7 weeks p.i. following trichostatin A 
induction. The resulting cell population was termed NIH3T3int cells. (B) Representative HIV-1 integration standard amplifica-
tion based on NIH3T3int cells plotted as a function of the natural logarithm of the concentration of HIV-1 (log concentration) 
versus the values of the PCR cycle threshold. The correlation coefficient R2 and the slope of the correlation are given.
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Validation of the quantitative PCR for the detection of HIV-1 integrants in the mouse genome Figure 5
Validation of the quantitative PCR for the detection of HIV-1 integrants in the mouse genome. (A) Technical val-
idation of species-specific HIV-1 integration PCRs on genomic DNA from mouse NIH3T3int cells or human HeLaint cells (20). 
Levels of HIV-1 integrants from the complete standard PCR reaction were set to 100% and levels determined for several spe-
cificity controls are given relative to that (omission (-) of LTR primer #1521, omission (-) of cellular anchor primer pair (B1, 
#2194 and #2231 (mouse) or Alu, #1519 and #1520 (human), omission (-) of first round PCR reaction). (B, C) Validation of the 
mouse integration PCR in a dynamic infection context. Parental NIH3T3 cells were infected with VSV-G HIV-CMV-GFP, carry-
ing either a wildtype integrase (IN wt) or a catalytically inactive integrase mutant (IN(D64V)). Where indicated, the NNRTI efa-
virenz was added 1 h prior to infection. (B) Infected NIH3T3 cells were monitored for levels of total HIV-1 cDNA on day 1 p.i. 
(C) On day 7 p.i., cells were analyzed for the presence of integrated HIV-1 cDNA applying the mouse integration PCR.
 

	


7

	











:
$
"


2

#

$


:

8
9

&



*



*


$
*
!
)
5% $($

@
 $($
*' 

	

7


	

%
*

"
!







8
9



*
#


2
#

$


:

8
9


4



A




	
	
3










:
$
"


2

#

$


:

8
9

 5"
93%3
&'(")
&*'2)
0"-$1 0"-$1
9+
9&87)
9+
9&87)
9+
9&87)
9+
9&87)Retrovirology 2008, 5:58 http://www.retrovirology.com/content/5/1/58
Page 9 of 16
(page number not for citation purposes)
HIV-1 integration is inefficient in mouse T-cell lines Figure 6
HIV-1 integration is inefficient in mouse T-cell lines. (A) Human and mouse T-cell lines, infected with VSV-G HIV-CMV-
GFP (see also results in Figs. 1–3), were analyzed for levels of HIV-1 integrants using species-specific integration PCRs (Figs. 4, 
5 and [6]). Triplicate samples were analyzed. (B) The Relative-Integration-Frequency was calculated as the number of integrants 
on day 7 p.i. (Fig. 6A) relative to the total amount of HIV-1 cDNA on day 1 p.i. (Fig. 3A) for the identical T-cell infection. -(C) 
Furthermore, the relative CMV-driven Transgene- Expression-per-Integrant was deduced from the identical experiments and 
calculated as the ratio of the percentage of GFP-positive cells on day 3 p.i. (Fig. 2B) relative to the number of integrants per ng 
cellular DNA on day 7 p.i. (Fig. 6A). In (B) and (C) the resulting ratio × 100 is given in arbitrary units, and the arithmetic means 
± S.E.M. of 3–5 independent experiments each with duplicates or triplicates are shown.
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Following infection with a near-full length HIV-1NL4-3, 
mouse T-cells do not support early viral gene expression
Finally, we sought to confirm the key findings also in the
context of an infection with a near-full length HIV-1NL4-3.
This replication-deficient, envelope-deleted molecular
proviral clone carries an egfp reporter gene within the nef
locus driven by the 5'-LTR, and virions were also VSV-G
pseudotyped and loaded with BlaM-Vpr during produc-
tion. Following infection with this virus, the Relative Post-
Entry Efficiency in TIMI.4 and R1.1 mouse T-cells was 62-
to 65-fold lower compared to human MT-4 (Fig. 7C) or
Jurkat T-cells (data not shown), and thus in a range simi-
lar to that seen for the lentiviral vector (55- to 235-fold;
Fig. 2C), despite the cyclin T1-dependence of gene expres-
sion. Of note, the post-entry restriction was not overcome
at an MOI > 5, determined by saturating virion fusion
Mouse T-cells do not support early viral gene expression following infection with a near-full length HIV-1NL4-3 Figure 7
Mouse T-cells do not support early viral gene expression following infection with a near-full length HIV-1NL4-3. 
(A-C) T-cell lines and (D-F) primary T-cells of mouse and human origin were challenged with VSV-G pseudotyped HIV-1NL4-3 
GFP virions carrying BlaM-Vpr and analyzed for virion fusion and early HIV-1 gene expression in principle as described in the 
legends to Figs. 1, 2. Shown are the arithmetic means ± S.D. Panels C and F depict the Relative- Post-Entry-Efficiency calculated 
as described in the legend to Fig. 2.
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conditions in the respective mouse T-cell lines (data not
shown). Importantly, relative to T-cells from a human
donor, a pool of primary T-cells from BALB/c mice also
displayed a severely reduced Relative-Post-Entry-Effi-
ciency following infection with VSV-G HIV-1NL4-3 GFP
(55-fold; Fig. 7F).
Furthermore, in cell aliquots removed on day 1 and 2 p.i.
from the experiment shown in Figs. 7A–C, levels of total
HIV-1 cDNA were quite similar in the cross-species com-
parison with infected mouse T-cell lines harbouring 1.4-
to 4-fold higher levels than human MT-4 T-cells (Fig. 8A,
upper panel). Most notably, levels of episomal 2-LTR cir-
cles were found to be drastically elevated in TIMI.4 T-cells
(51- to 245-fold) and modestly enhanced in R1.1 T-cells
(5- to 7-fold) relative to the human counterpart (Fig. 8A,
lower panel). Following normalization with levels of de
novo synthesized HIV-1 cDNA, 2-LTR circle levels were sta-
tistically indistinguishable for R1.1 and MT-4 T-cells. For
reasons unknown, the DNase-resistant, production-
related plasmid contamination in stocks of VSV-G HIV-
1NL4-3 GFP was typically 2–3 orders of magnitude higher
compared to VSV-G HIV-CMV-GFP, and, as a conse-
quence, integration could not be reliably quantified for
the former virus in T-cells from either species (data not
shown).
In an attempt to circumvent this technical limitation, we
reasoned that the reduced ability of mouse T-cells to form
proviruses should be reflected in a loss of cell-associated
HIV-1 cDNA during prolonged passage. Consequently,
cells were challenged with the replication-defective VSV-G
HIV-1NL4-3GFP carrying BlaM-Vpr and continuously culti-
vated for four weeks. First, levels of virus entry (6 h p.i.;
data not shown), de novo synthesized HIV-1 cDNA (Fig.
8B), and 2-LTR circles (data not shown) were fairly com-
parable on 1 day p.i., confirming the intact early phase of
the replication cycle and successful nuclear import of the
preintegration complex. In contrast, a massive loss of cell-
associated HIV-1 cDNA was observed in all three mouse T-
cell lines at day 14 p.i. (Fig. 8B; 102- to > 2317-fold reduc-
tion) with levels in passaged TIMI.4 cells at background.
On day 28 p.i., levels of amplified HIV-1 cDNA were fur-
ther reduced in R1.1 and S1A.TB cells. Collectively, these
results provide additional evidence that HIV-1 cDNA,
despite nuclear localization, cannot efficiently integrate
into the genome of mouse T-cell lines, resulting in a
largely abortive infection.
Discussion
The mapping of HIV-1 replication barriers in non-human
cells has allowed the identification and molecular charac-
terization of critical host factors [3,31] and potent restric-
tion factors [32,33]. This has, on one hand, expanded our
understanding of fundamental processes in the host-virus
HIV-1 reverse transcription and nuclear import of the pre- integration complex are well supported in mouse T-cell lines  after infection with nearly full-length HIV-1NL4-3 Figure 8
HIV-1 reverse transcription and nuclear import of 
the pre-integration complex are well supported in 
mouse T-cell lines after infection with nearly full-
length HIV-1NL4-3. (A) The relative levels of (upper panel) 
total HIV-1 cDNA, and (lower panel) 2-LTR circles were 
quantified in human (MT-4) and mouse (TIMI.4, R1.1) T-cell 
lines infected with VSV-G HIV-1NL4-3 GFP on day 1 and 2 p.i., 
and samples derived from the experiment shown in Figs. 7A-
C. At the indicated time points p.i. cell aliquots were taken 
and DNA analyzed by real-time PCR for the respective HIV-
1 cDNA species. Duplicate samples were quantified. (B) 
Dynamic of HIV-1 cDNA load in passaged T-cell lines. Cells 
infected with VSV-G HIV-1NL4-3 GFP BlaM-Vpr were culti-
vated for four weeks. The relative levels of total HIV-1 
cDNA shown are derived from DNA analyses of two inde-
pendent infections from cell samples taken on days 1, 14, and 
28 p.i. *below detection limit.
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interaction and, on the other hand, fuelled efforts to
develop genetically altered rodents and non-human pri-
mates that are highly permissive for HIV-1 [1,14,34,35].
In the current study we demonstrate that T-cells from mice
restrict HIV-1 replication at the level of integration.
We examined the fate of the virion and viral genome
through consecutive steps in the early infection phase fol-
lowing a single challenge with dual-reporter HIV-1 viri-
ons. To circumvent potential HIV-1 Tat/cyclin T1-
dependent, species-specific differences in LTR transactiva-
tion [3], we used an HIV-based vector encoding for GFP
driven by a CMV promoter. This experimental approach
corroborated the finding reported in three earlier studies
that primary and immortalized T-cells from mice harbor a
severe post-entry restriction for HIV-1, in the context of
infections with virions carrying either HIV envelopes or
VSV-G [19-21]. Of note, analogous experiments using a
near-full length HIV-1NL4-3, in which the GFP reporter is
driven off the 5'-LTR (Fig. 7), demonstrated a similar
defect in the Relative-Post-Entry-Efficiency in mouse T-
cells.
Carefully controlled virion fusion and real-time PCR anal-
yses showed that reverse transcription per fused HIV-1
particle is at least as efficient in T-cells from mice as in
their human counterparts. Furthermore, relative levels of
2-LTR circles were comparable or in some instances even
markedly elevated in mouse T-cells (Figs. 3D, 8A), dem-
onstrating transfer of the pre-integration complex into the
nucleus. In contrast, Baumann et al. [20] reported reduced
efficiencies at both of these replication steps in the identi-
cal mouse T-cell lines used in our study. The reason for
these discrepancies is currently unclear. In this report [20]
we noted several differences to our study, including (i) a
side-by-side comparison of infected mouse T-cells only
with mouse NIH3T3 fibroblasts, but not human T-cells,
(ii) a lack of correlative evaluations of consecutive replica-
tion steps, (iii) a lack of control for residual proviral plas-
mid contamination in virus inocula, and (iv)
quantification of HIV-1 cDNA species without a PCR-
based normalization for corresponding cell equivalents.
In line with our observations, Tsurutani et al. [21] found
that reverse transcription proceeds normally in mouse T-
cells and that levels of 2-LTR circles were similar in the
cross-species comparison following an HIV-1 IN wt infec-
tion. Using a cassette ligation-mediated PCR these authors
noted a qualitative reduction in integrants in primary
lymphocytes from mice. However, based on 2- to 8-fold
lower relative 2-LTR circle levels for infections with an
integrase-defective HIV-1, Tsurutani et al. located the
restriction exclusively at the level of nuclear import in
mouse cells. Conceivably, the abundance of 2-LTR circles
can be affected by a large number of parameters including
the levels of reverse transcribed viral DNA, the efficiency
of nuclear import of the pre-integration complex, the effi-
ciency of integration, the activity of cellular ligases of the
non-homologous DNA end joining pathway, the forma-
tion frequency of other episomal HIV-1 cDNA species (1-
LTR circles and auto-integrants), the degradation kinetics
of episomes, the time point p.i. as well as the frequency of
cell division [36-39]. Of note, the ratio of 2-LTR circles per
total HIV-1 cDNA was ~100- to 1000-fold lower in the
identical T-cell lines infected with the lentiviral vector
(0.008% – 0.01%; Fig. 2A, B) compared with the near full-
length HIV-1NL4-3 virus, 0.6%; 1.2% and 25.6% (see Fig.
8A, B). In addition to the difficulties in assessing 2-LTR
circle levels discussed above, this also suggests marked
construct-dependent differences in the formation of these
HIV-1 cDNA episomes. While the presence of 2-LTR cir-
cles can be taken as unambiguous proof for nuclear trans-
fer of pre-integration complexes, a quantitative
assessment of this episomal DNA species, in light of the
plethora of factors influencing its steady-state levels, in
our view, does not allow a selective examination and con-
clusive interpretation of the efficiency of nuclear import
in a cross-species comparison.
As a technical advance, we established a nested real-time
PCR to specifically detect integrants in the mouse
genome. Of note, repetitive B1 elements in the mouse
genome are approximately 5-fold less abundant than Alu
elements in the human genome (2% versus 10%) [40],
which potentially renders the mouse HIV-1 integration
PCR slightly less sensitive. This does, however, not affect
the quantification of absolute integrant numbers per
genome equivalent, since each species-specific HIV-1 inte-
gration standard was calibrated against a total HIV-1
cDNA quantification in long-term passaged NIH3T3int
and HeLaint cells. This strategy thus allows a direct com-
parison of absolute levels of integrants between two spe-
cies.
First and most importantly, we identify and quantitatively
describe a severe limitation at the level of provirus forma-
tion in infected mouse T-cell lines, in which pre-integra-
tion complexes had entered the nucleus. Based on the
above arguments, we cannot formally exclude a quantita-
tive limitation in nuclear import in mouse T-cells based
on the 2-LTR circle analyses, however, we can clearly dem-
onstrate a paramount defect at the level of integration.
Different degrees of integration impairment were noted
with TIMI.4 cells displaying the most drastic restriction,
while Relative-Integration-Frequency values in R1.1 and
S1A.TB cells were 18- to 54-fold lower compared to
human MT-4 cells. As an important characteristic, the bar-
rier was not overcome at high MOIs which favors the
hypothesis of a lacking supportive cellular factor rather
than the presence of an inhibitory or restriction factor.Retrovirology 2008, 5:58 http://www.retrovirology.com/content/5/1/58
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Furthermore, analysis of the Transgene-Expression-per-
Integrant suggests that a cyclin T1-independent transcrip-
tional defect may impose an additional peri-integrational
limitation for a productive HIV-1 infection at least in
some mouse T-cell lines. Conceptually, integration into
transcriptionally unfavorable sites in the host genome
[41,42] could result in such a phenotype.
The fate of HIV-1 cDNA following nuclear entry is a step
in the retroviral replication cycle that only recently is
being recognized to be dependent on and modulated by
specific host factors. Most notably, lense epithelium-
derived growth factor (LEDGF/p75) is a chromatin-associ-
ated host protein that directly interacts with integrase and
apparently tethers the pre-integration complex to the
chromosome [43-47]. LEDGF/p75 is, on one hand, essen-
tial for an efficient integration process [27,48] and, on the
other hand, likely involved in the targeting of HIV-1 inte-
gration into transcription units in human cells [49,50].
Both of these characteristics make LEDGF/p75 a potential
candidate for the observed peri-integrational deficits in
mouse T-cells. Interestingly, murine and human LEDGF/
p75 are highly homologous and all known functional
regions are 100% conserved. Embryonal fibroblasts from
Psip1/Ledgf knockout mice displayed severely reduced lev-
els of HIV-1 vector integration [42]. Of note, in this iso-
genic mouse context, a ~10-fold reduction in HIV-1
integrants coincided with a modest, ~1.5-fold increase in
2-LTR circles, consistent with the relative constellation
seen for these two HIV-1 cDNA species in the cross-species
comparison in the majority of our experiments. Further-
more, a critical role of mouse LEDGF/p75 in gene-specific
integration was demonstrated in null cells both by map-
ping of residual integration sites and the observation of
reduced transgene expression levels per integrant [42].
Consequently, it could be highly informative to deter-
mine and potentially manipulate levels of endogenous
LEDGF/p75 in restricted mouse T-cells.
Additional cellular proteins of interest include emerin and
barrier-to-autointegration factor, which have been pro-
posed to contribute to the appropriate nuclear localiza-
tion of the viral DNA for chromatin engagement prior to
integration in human cells [26], although this is still con-
troversial [51]. Of potential relevance for a scenario
involving an inhibitory activity, Zhang et al. identified
p21Waf1/Cip1/Sdi1 as a cellular factor that can influence the
sensitivity of human hematopoietic precursors for infec-
tion by HIV-1 at a post-entry step [52]. Specifically,
expression of p21 in these human cells altered the fate of
HIV-1 cDNA in the nucleus, apparently promoting the
formation of episomal 2-LTR circles at the expense of inte-
gration.
Mice and rats are the prime candidates for the develop-
ment of an immunocompetent, multi-transgenic small
animal model. Primary target cells from both rodents
share the inability to support virion entry and efficient
transcription, and these limitations can be overcome by
transgenic expression of the HIV-1 receptor complex
[1,2,35] or human cyclin T1 ([6,14], and C.G. and O.T.K.,
unpublished observation), respectively. Contrasting the
severe early-phase restriction in mouse T-cells, rat T-cells
efficiently support all steps of the HIV-1 replication cycle
up to and including integration [6]. Thus, mice appear to
impose at least one additional replication barrier com-
pared to rats which highlights the complexity of the task
to develop genetically altered mice that are fully permis-
sive for HIV-1 infection. The here identified restriction at
the level of integration in mouse T-cells will facilitate the
identification of critical host factors towards this goal.
Methods
Animals
Female BALB/c mice were obtained from Charles River
Laboratories (Sulzfeld, Germany). Animals were kept in
the central animal facility of the University of Heidelberg.
Cells
The mouse T lymphoma cell lines S1A.TB.4.8.2 (S1A.TB)
(TIB-27; BALB/c strain), TIMI.4 (TIB-37; C57BL/6 strain)
and R1.1 (TIB-42; C58.J strain) were obtained from the
American Type Culture Collection and cultivated in Dul-
becco's modified Eagle medium supplemented with 10%
fetal calf serum or horse serum (R1.1), 1% penicillin-
streptomycin, and 1% L-glutamine (all from GIBCO).
Human T-cell lines MT-4 and Jurkat, the adherent cell
lines TZM-bl, 293T, HeLaint, and mouse fibroblast cell line
NIH3T3 cells (CRL-1658; NIH/Swiss strain) were culti-
vated as reported [6,7,53-55]. Primary T-cells from Ficoll-
gradient purified peripheral blood mononuclear cells
from healthy human donors were activated by phytohae-
magglutinin-P (1 μg/ml) and human recombinant inter-
leukin-2 (IL-2) (20 nM, BioMol, Germany) as reported
[25,35,53,56]. Primary T-cells from BALB/c mice were
prepared from spleens, which had been removed asepti-
cally from sacrificed animals. Single-cell suspensions were
prepared by pushing tissue pieces through a nylon mesh
screen (70-μm-pore-size nylon, Becton Dickinson). The
cell suspension was washed once with PBS and erythro-
cytes were lysed for 3 min with ACK lysis buffer, followed
by another PBS wash. Single-cell splenocyte suspensions
were cultivated in supplemented medium and activated
with Concanavalin A (1 μg/ml) and IL-2 as reported [56],
yielding proliferating cultures containing ~90% CD3-pos-
itive T-cells.Retrovirology 2008, 5:58 http://www.retrovirology.com/content/5/1/58
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DNA extraction
Cellular and viral DNAs were extracted using Qiagen
DNeasy Tissue Kits®. Samples for quantitative HIV-1 inte-
gration PCR were extracted according to the method of
Hirt [57,58]. Briefly, 5 × 105 cells were pelleted and care-
fully resuspended in 160 μl HIRT Solution I. Next, 10 μl
Proteinase K (20 mg/ml) and 200 μl HIRT Solution II
were added and the cells were incubated for 30 min at
56°C. Then, 100 μl of 5 M sodium chloride were added to
the reaction prior to overnight incubation at 4°C. After-
wards, chromosomal DNA was pelleted and the superna-
tant removed. The HIRT pellets were then extracted with
phenol-chloroform-isoamyl alcohol (25:24:1), ethanol
precipitated in the presence of glycogen, and washed in
70% ethanol prior to resuspending the DNA pellet in elu-
tion buffer (Qiagen).
Virus stocks
VSV-G pseudotyped stocks of a three-plasmid HIV-1-
based GFP vector [59] (HIV-CMV-GFP) or of HIV-1NL4-3 E-
GFP [60], carrying BlaM-Vpr, were generated in 293 T cells
by calcium phosphate DNA precipitation in principle as
described [6,7]. Virus stocks were characterized for p24
CA concentration by antigen enzyme-linked immuno-
sorbent assay and for infectious titer on TZM-bl cells,
respectively [53]. Virus stocks were treated with DNase
(Turbo DNase, Ambion, Dresden, Germany) for 1 h at
37°C (5 IU per 10 μl of concentrated virus stock) to
reduce the degree of plasmid contamination prior to chal-
lenge of target cells.
HIV-1 virion-fusion assay and gene expression analysis
Target T-cells (5 × 106) were left untreated or pretreated
with efavirenz (100 μM, Bristol-Myers Squibb, Uxbridge,
UK) for 1 h, or a hybridoma supernatant containing anti-
VSV-G monoclonal antibody I1 [24] for 15 min at 37°C.
Subsequently, cells were infected with BlaM-Vpr-loaded
VSV-G HIV-1 for 6 h, washed and stained overnight with
CCF2/AM dye. Fusion was monitored with a three-laser
BD FACSAria Cell Sorting System (Becton Dickinson, San
Jose, CA) as reported [6,22,23,25]. On day 3 p.i., the per-
centage of GFP-positive cells was measured in the identi-
cal cultures on a FACSCalibur using BD CellQuest Pro
4.0.2 Software (BD Pharmingen).
Quantification of total HIV-1 cDNA and 2-LTR circles
Levels of total HIV-1 cDNA and 2-LTR circles in infected
cell lines were measured by quantitative PCR using the
ABI 7500 sequence detection system (Applied Biosystems,
Foster City, CA) as reported in detail [25]. For PCR stand-
ard curves, dilutions of pHIV-1NL4-3 and pU3U5, respec-
tively, covering 5 logs were used, supplemented with DNA
extracted from uninfected cells. Results for HIV-1 cDNA
species were normalized to the amount of cellular DNA,
which was quantified in a parallel amplification of the
mouse GAPDH gene or human RNaseP gene (Applied
Biosystems), respectively. Genomic standards were
derived from dilutions of genomic DNA extracted from
uninfected cells. All samples were run in duplicate. Data
analysis was performed with the 7500 System Software
(Applied Biosystems). Of note, for all HIV-1 cDNA analy-
ses values obtained for parallel infections of efavirenz-
treated cultures were subtracted from values of untreated
cultures to account for residual proviral plasmid contam-
ination in DNAse-treated virus inocula. For total HIV-1
cDNA analyses shown in this manuscript for VSV-G HIV-
CMV-GFP (Figs. 1, 2, 3, 4, 5, 6) or VSV-G HIV-1NL4-3 GFP
(Figs. 7, 8), the subtracted signals ranged between 0.07 –
0.65% or 0.3 – 4.6% of the untreated infection, respec-
tively. However, in several experiments with other VSV-G
HIV-1NL4-3 GFP stocks this background signal reached lev-
els above 60% (despite DNAse treatment), not allowing a
reliable quantification of total HIV-1 cDNA or integrants.
Quantification of integrated HIV-1 cDNA
The strategy to quantify HIV-1 integrants in the mouse
genome by real-time PCR and the generation of a mouse
integration standard cell line, NIH3T3int  cells, was
adapted from the protocol established for the rat species
[6]. Briefly, HIV-1 integrants were amplified in the first
reaction by one primer annealing to the LTR (primer
#1521 [28]), which contains a lambda-phage heel
sequence at the 5'-end, and by two outward-facing prim-
ers that target the highly redundant consensus sequence
within the mouse B1  gene [40] (primers #2194, 5'-
ACAGCCAGGGCTACACAGAG-3' and #2231, 5'-CCTC-
CCAAGTGCTGGGATTAAAG-3'). The first-round ampli-
con was then amplified in a second reaction with a
lambda-specific primer (primer #1522 [28]) and an LTR
primer (primer #1523, [6]) and an LTR-specific probe
(probe #1524, [6]). The second-round cycling conditions
were identical to those used to determine the total
amounts of HIV-1 cDNA and 2-LTR circles [25]. For the
detection of HIV-1 integrants in infected human cells, the
conditions and reagents were identical to those reported
[6]. For each integration PCR, a specificity control reaction
was run in parallel in which the cellular primer pair was
omitted during the first round reaction and this value was
subtracted from the total signal (not more than 20% of
the absolute signal). For integration standard curves, dilu-
tions of genomic DNA derived from NIH3T3int  and
HeLaint cells covering 3.1 logs were used (see also Fig. 4B).
Criteria for standard validity included the slope, which
indicates the efficiency of the PCR reaction within a
defined copy range using diluted cellular DNA carrying
defined amounts of integrated provirus (ideally 3.32, cor-
responding to a 100% efficient reaction). In addition,
only integration PCR assays in which the standard
reached a R2 coefficient > 0.9 were analyzed. The lowest
detection standard of the PCR was 0.04 and 0.12 HIV-1Retrovirology 2008, 5:58 http://www.retrovirology.com/content/5/1/58
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integrants per ng DNA for integrated provirus in mouse
and human genomic DNA, respectively.
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